REDEEM - access to BCX9930
Research type
Research Study
Full title
An Open-label Study to Evaluate the Long-term Safety of BCX9930 Monotherapy in Subjects with Paroxysmal Nocturnal Hemoglobinuria Who Previously Received BCX9930 in a BioCryst sponsored Study
IRAS ID
1006985
Contact name
Kathryn Hutchinson
Contact email
Sponsor organisation
BioCryst Pharmaceuticals Inc
Eudract number
2021-006776-17
Clinicaltrials.gov Identifier
Research summary
The clinical trial is to provide continuing access to participants with PNH, who have successfully completed a previous BioCryst clinical trial, were determined to be receiving a clinical benefit and who wish to continue to receive treatment. The trial will provide treatment for a further 48 weeks. Additional information is available at operations@ams-europe.com
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
22/NE/0233
Date of REC Opinion
20 Jun 2023
REC opinion
Further Information Favourable Opinion